Google
LUCD — LUCID DIAGNOSTICS INC (Healthcare >> Medical Devices)
LUCD FAQ
What is LUCD's ROE?
LUCID DIAGNOSTICS INC reports a Return on Equity (ROE) of -1,125.28%.
What is LUCD's dividend yield?
LUCID DIAGNOSTICS INC offers a dividend yield of 0.00%.
What is LUCD's Deepscope Quality Score?
Deepscope rates LUCD's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LUCD?
Deepscope's AI Timing Score for LUCD is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LUCD belong to?
LUCID DIAGNOSTICS INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 1.02
Price
0.02
(1.49%)
Day Change
|
|
|---|
LUCD, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.02 |
| PBV / Sector |
49.12 / 7.50
|
| Earning Per Share | -0.23 |
| PE / Sector |
N/A / 28.68
|
| PEG or PE/Growth / Sector |
N/A / 0.39
|
| Average 1M Daily Value |
1.02 M
GREAT
|
| Average 1W Daily Value |
0.79 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
39% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:04 |
| Symbol | LUCD |
| Name | LUCID DIAGNOSTICS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 190.76 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 196.48 / 18,060.39 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 360 Madison Avenue, New York, NY, United States, 10017
Phone: 917 813 1828
Website: https://www.luciddx.com
Employees: 82
Sector: Healthcare >> Medical Devices
Description: Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
